Pfaller, M.A., Rhomberg, P.R., Messer, S.A., Jones, R.N. and Castanheira, M. (2015) Isavuconazole, Micafungin, and 8 Comparator Antifungal Agents’ Susceptibility Profiles for Common and Uncommon Opportunistic Fungi Collected in 2013: Temporal Analysis of Antifungal Drug Resistance Using CLSI Species-Specific Clinical Breakpoints and Proposed Epidemiological Cutoff Values. Diagnostic Microbiology and Infectious Disease, 82, 303-313.
https://doi.org/10.1016/j.diagmicrobio.2015.04.008

has been cited by the following article:

• TITLE: Monte Carlo Analysis of Different Administration Regiments for Isavuconazole against Candida spp. and Aspergillus spp.

  AUTHORS: Jiuli Hu, Chanchan Hu, Xiaoqin Zhu

  KEYWORDS: Monte Carlo Simulation (MSC), Isavuconazole, Candida spp., Aspergillus spp.

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.12 No.12, December 24, 2021

  ABSTRACT: In our study, we aimed to optimize the dosage regimen of Isavuconazole against Candida spp. and Aspergillus spp. by Monte Carlo simulation (MSC). Pharmacokinetic parameters and microbiological data of Isavuconazole were collected. Then we used MSC to simulate 10,000 patients analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). With dosages of 100 mg, 200 mg, and 400 mg in oral group and dosages of 100 mg, and 200 mg in intravenous administration, all have different degrees of antifungal effect. But when the dosage regimen was 50 mg IV, the therapeutic effect of Isavuconazole against Aspergillus spp. and Candida spp. were not good.